OncLive.com✓

It's somehow time for our last day of ✨LIVE✨ filmings at this year's @myESMO #ESMO26 Congress! 🎥 Are you in Madrid and presenting key data? Reach out to our team to set up an exclusive interview. We would love to speak with you! Follow along for the latest updates from the meeting and to see who we have in the chair today 👉:

Adding iberdomide to daratumumab-dexamethasone significantly improved MRD-negative CR rates vs DVd in relapsed/refractory multiple myeloma. Sagar Lonial, MD, FACP, FASCO, breaks down the phase 3 EXCALIBER-RRMM results on OncLive®. Watch now: @SagarLonialMD @EmoryUniversity #mmsm #Iberdomide #EXCALIBERRRMM

Rash rates of 50% to 60% with amivantamab may not be a given. Edgardo Santos, MD, FACP, FASCO, and Wade Iams, MD, MSCI, discuss how COPERNICUS-style prophylaxis with subcutaneous dosing brought rash down to 20% to 30%. Watch all episodes of the OncLive® Insights series: @EdgardoSantosMD @StarlingOnc @WadeIams @TNOncology #lcsm #EGFR #Amivantamab

A @RoswellPark study showed survival benefits with the combination of bevacizumab and pazopanib in advanced clear cell kidney cancer #kcsm #oncology Read more:

📈 Prior exposure to ICIs increased the risk of mucocutaneous AEs, particularly dermatitis, in patients with FGFR2-altered solid tumors treated with lirafugratinib, according to a post hoc analysis of ReFocus. @myESMO #ESMO2026 #oncology Full story ➡️:

WATCH: Kimberly B. Hoang, MD, of @WinshipAtEmory, discusses considerations for tile-based brachytherapy in patients with brain tumors during International Brain Tumor Awareness Week. #btsm #oncology Sign up to read more insights:

WATCH 🎥: Masatoshi Kudo, MD, PhD, highlights next steps for hepatocellular carcinoma research during #LiverCancerAwarenessMonth. #oncology See our gastrointestinal cancers page for more insights ➡️:

T-DXd plus pertuzumab improved systemic and intracranial outcomes vs THP in pts w/ HER2-positive advanced or metastatic breast cancer and brain metastases in an exploratory analysis of DESTINY-Breast09. @myESMO #ESMO2026 #bcsm #oncology Full story ➡️:

The combination of relacorilant, nab-paclitxel, and bevacizumab produced clinically meaningful activity in platinum-resistant ovarian cancer, with more pronounced outcomes observed in patients naive to bevacizumab #ovca #oncology Read more on the phase 2 BELLA study:

Updated @ASTRO_org guidelines recommend moderate hypofractionation over conventional fractionation in localized prostate cancer across risk groups where definitive EBRT is elected; and ultrahypofractionation as a standard option for many patients, including those with intermediate-risk disease #pcsm #oncology Read more on the updates:

Which CDK4/6 inhibitor do Dana-Farber experts reach for first in HR+ MBC? Get their answer, plus 4 more CDK4/6 questions, from the OncLive® State of the Science Summit®: Breast Cancer in Boston.

🗞️Just in: Based on an IMDC recommendation, the phase 3 IMpactMF trial evaluating imetelstat in patients with myelofibrosis that is relapsed/refractory to a JAK inhibitor is being discontinued #mpnsm #oncology Read more:

sac-TMT plus pembrolizumab improved PFS in the first-line treatment of PD-L1–negative, advanced nonsquamous NSCLC without EGFR or ALK alterations in the phase 3 OptiTROP-Lung06 trial @myESMO #ESMO26 #lcsm #oncology Read more:

Live from the #ESMO26 Congress: @PTarantinoMD, and @OncHahn, join host @CParkMD, for a real-time read on the breast and genitourinary cancer data shaping practice! 🌍 Watch the full conversation:

That's a wrap on a great lineup of conversations! ⚽🎥 Chandler Park, MD takes OncLive On Location to the ESMO Congress 2026, connecting with experts to explore emerging data, clinical advances, and evolving perspectives across oncology. Ready to catch the highlights? Relive the key moments now: #ESMO26

Host @CParkMD sits down with Alexandra Drakaki, MD, PhD, and @sonpavde, for a real-time read on perioperative EV, ctDNA-guided adjuvant therapy, and what’s next in muscle-invasive bladder cancer at the 2026 ESMO Congress! 🌎 Tune in today: #blcsm #ESMO26

With bispecifics, ADCs, and CAR T all targeting BCMA, sequencing in relapsed/refractory myeloma is the real question. Hans Lee, MD, Jing Christine Ye, MD, MSc, Douglas W. Sborov, MD, MS, and Paul G. Richardson, MD weigh in. Watch now on OncLive®: @SarahCannonDocs @UTMDAnderson @huntsmancancer @DanaFarber #mmsm #BCMA #Bispecifics

Is docetaxel still the bar after immunotherapy in squamous NSCLC? Jacob Sands, MD, Narjust Florez, MD, Christian Rolfo, MD, PhD, and Edward S. Kim, MD, MBA weigh where ADCs and bispecifics fit in second line. Watch the OncLive® Peer Exchange: @sands_jacob @NarjustFlorezMD @DanaFarber @ChristianRolfo @OSUCCC_James @DrEdKim @cityofhope #lcsm #NSCLC #ADCs

📰Just in: T-cell–redirecting therapies continue to demonstrate improvements in early-relapse myeloma. Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology

📰 The European Commission has approved T-DXd monotherapy for patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with a taxane and HER2-directed therapy. #bcsm #oncology Read more ➡️:

Oncology fellows: share your genitourinary cancer research with peers and leading GU faculty at the OncLive® National Fellows Forum, Feb 10, 2027, in San Francisco. Abstracts due Dec 31. Submit your abstract: #pcsm #blcsm #kcsm